entrectinib

roslitric anae brand paerutoe vikrayinche entrectinib, undhi naan-small sell oopiritittula cancer mariyu ntrk fusion-positive ghana kanitulaku chikitsa cheyadaaniki upayoginche cancer nirodhaka aushadham. idhi tropomyosin receptor kines (truck) eah, bii mariyu sii, sii-rose ankogene 1 (rose 1) mariyu anaplastic lymphoma kines (alk) yokka selective tyrosine kines inhibitor (tiki).
atyanta saadhaarana dushprabhavalalo alasata, malabaddhakam, diasgetia (ruchi aatamkaalu), vaapu (dravam nilupudalatoe vaapu), maikamu, atisaaram, vikaram (jabbupadinatlu anipinchadam), dicesthesia (taakinappudu asahyakaramaina mariyu asaadhaarana anubhooti), dysnia (swaasa teesukovadamlo ibbandi), raktaheenata (erra rakta kanaala sankhya takkuvagaa undatam), baruvu peragadam, perigina rakta creatine (moothrapindaala samasyalaku sanketamgaa unde avakaasam), noppi, abhignaa rugmatalu (aalochinche, neerchukunee mariyu gurthunchukune saamardhyamtho samasyalu), vaantulu, daggu mariyu jwaram unnaayi.
idhi 2019 augustulo united stateslo, 2020 maeloe australialo mariyu 2020 joolailo european unionlo vaidya upayogam kosam aamodinchabadindi.
vaidya upayogaalu.
samyukta rashtraallo, cancer luu undhi (oka nirdishta janyu lakshanam (biomarker) kaligi unna) rogulaku chikitsa cheyadaaniki entrectinib suuchimchabadutumdi. idhi ghana kanitulu unnavaarilo upayoginchabadutundih
pannendu samvatsaraala kante takkuva vayassu unnavaarilo entretinib upayogam kosam aamodinchabadaledu.
european unionlo, neurotrophic tyrosine receptor kinace (enn. tii. aarr. keey) janyu kalayikanu vyaktam chese ghana kanitulato pannendu samvatsaraalu mariyu anthakante ekkuva vayassu unna peddalu mariyu koumaaradasalo unnavaari chikitsa kosam monotherapyga entrectinib suuchimchabadutumdi,
gatamlo maroka inhibitorsto chikitsa cheyani maroka positive, adhunaatana naan small sell oopiritittula cancer (nslc) unna peddala chikitsa kosam kooda idhi suuchimchabadutumdi.
dushprabhaavaalu.
entrectinib yokka saadhaarana dushprabhavalalo alasata, malabaddhakam, diasgetia, vaapu, maikamu, atisaaram, vikaram, diasthesia, dyspnia, myelgia, abhignaa balaheenata, baruvu peragadam, daggu, vaantulu, jwaram, arthralgia mariyu drushti rugmatalu unnaayi.
entrectinib yokka atyanta teevramaina dushprabhaavaalu raktaprasarana gunde vaiphalyam, kendra naadii vyavastha prabhavalu, asthipanjara pagullu, hepatotoxicity, hyperuresemia, cuty podigimpu mariyu drushti rugmatalu.
charitra.
U loe.ess., entrectinib neuroblastoma chikitsaku anaadha aushadha hodha mariyu arudaina pediatric vyaadhi hodha mariyu trca-, truckub-, trkesi-, trkesi alk-positive naan-small sell oopiritittula cancer (nslc) mariyu metastatic colorectal cancer (mcrc) chikitsaku anaadha aushadha hodha kaligi undhi. idhi neuroblastoma kosam oka yuu anatha hodaanu kaligi undhi. undhi, metastatic naan-small sell oopiritittula cancer mariyu ntrk janyu kalayika-positive ghana kanitulu unna vyaktulaku fda aamodinchina entrectinib. idhi medaduku vyaapinchina cancerlo pratispandananu kooda choopinche maroka mariyu ntrk rendintinee lakshyamgaa chesukovadaniki roopondinchina modati fda-aamodinchabadina chikitsa. juun augustu, japan aarogya, kaarmika mariyu sankshema mantritva saakha (emechaldableu) ntrk fusion-positive, adhunaatana punaraavruta ghana kanitulato vayojana mariyu pediatric rogula chikitsa kosam agentnu aamodinchindi.
yuu.ess. vividha rakaala ghana kanitulato 355 mandhi rogula naalugu clinical trials nundi vacchina saakshyaala aadhaaramgaa phud und drugg administration (fda) entrectinibnu aamodinchindih trial 1 (udract 2012-000148-88), trial 2 2, trial 3 3, mariyu trial 4 4. eee trials united states, eurup mariyu asea/pasiphik praantamloo jarigaayi.
fda manjuru chesina entretinib vegavantamaina aamodam, praadhaanyata sameeksha, purogati chikitsa mariyu anaadha aushadha hodha. roslitric aamodam genentech, ink kuu manjuru cheyabadindi.
charya yokka yantraangam.
tumour genesis prakriyaloo tarachugaa protein kines activation sanghatanalu untaayi, ivi utparivartanalu ledhaa chromosome punarvyavastheekaranala phalitamgaa undavacchu. janyu punarvyavastheekaranalu, rajyangabaddhamga sakriyam cheyabadina fusion tyrosine kines graahakaala vyakteekaranaku daariteestaayi, gatha moodu dasabdaluga praanaantakaala yokka saadhaarana lakshanamgaa ekkuvagaa gurtinchabaddaayi, mariyu eee punarvyavastheekaranalanu aushadha abhivruddhiki lakshyaluga upayoginchadam dwara vijayam pradarsinchabadindi.
kanitilo ituvanti janyu fusionla vyakteekarana 'ankogene vyasanam' anie piluvabade oka drugvishayaanni srushtinchagaladu, dheenilo kaniti asaadhaarana kines maargam dwara sanketalapai aadharapadi untundi, tadwara daani manugadanu andistundi mariyu chinna anuvu tyrosine kines inhibitor aushadhaalato lakshya nirodhakataku sunnitamaina vistarananu konasaagistundi. eee tyrosine kines fusion janyuvula dwara encode cheyabadina proteinla vyakteekarana, chaalaa sandarbhaallo, praanaantaka samalakshanamlo palgonna klishtamaina diguva maargaalanu sakriyam cheyagala saamarthyam kaligina ancogenic driverluga swatantramgaa panichestundani choopabadutundi, phalitamgaa kanaalu "inn vitro" gaa marutayi. maanava cancerlalo punarvyavastheekaranaku guraina konni mukhyamaina kineslalo anaplastic lymphoma kines (alk), maroka kines mariyu neurotrophic receptor tyrosine kines (ntrx) unnaayi.
entrectinib anedi moodu truck proteinlaku (varusaga "ntrk1,2, mariyu 3" janyuvula dwara encode cheyabadina) alaage maroka, mariyu alk receptor tyrosine kineslaku, takkuva nanomolar saandratala vadda, nirdishtatatoe kuudina selective tyrosine kines inhibitor. eee aushadhaanni noti dwara, rojuku okasari istaaru, mariyu "ntrk 1/2/3, alk" ledhaa "ros1" loe kanitulu fusionlugaa unnatlu choopinchina rogulalo adhyayanam chestunnaru. maroka inhibitorga, entrectinib cellular anty-proliferative adhyayanaalalo మరొకకు vyatiraekamgaa 36 retlu ekkuva saktini kaligi undani niroopinchindi, idhi vaanijyaparamgaa labhinche maroka maroka inhibitor, chryzotinibto poliste. 
vii573emm ntrk1, vii573emm ntrk1, vii573emm ntrk1 vanti sambhaavya truck nirodhakata utparivartanalaku vyatiraekamgaa entrectinib inn-vitro saamarthyaanni kooda pradarsinchindi.
clinical abhivruddhi.
entrectinib prastutam starterk-2 anae global faze II basket clinical trial loe pareekshinchabadutondi. rendu konasagutunna faze 1 trials nundi madhyantara phalitaalu 2016 eprillo jarigina cancer research conferencelo nivedinchabaddaayih entrectinibto chikitsa pondina rogulalo, naluguru rogulaku kanitulu unnaayi, veetilo chinna-kaani sell oopiritittula cancer (nslc), mcrc, lalajala grandhi cancer mariyu astrocytoma unna rogulu unnaaru.
enn. tii. aarr. aarr fusionlu unna rogula modati dasha adhyayanaalalo entrectinibto kanipinche praathamika phalitaalu eee janyu punarvyavastheekaranalatho kanitulu unna rogulalo entrectinib vadakanni pariseelinchadaaniki open-label, multicenter, global, faze II basket adhyayananni praarambhinchadaaniki daariteesaayi. roogi anni itara pravesha pramaanaalaku anugunamgaa untaadani bhaavinchi, adhyayanam oka ntrk/ros1/alk fusion yokka aadharalu kaligina ghana kaniti unna yea roginainaa namodu chestundi. atuvanti kaniti rakalaku udaaharanalalo nslc, mcrc, lalajala grandhi cancer, sarcoma, melanoma, thyroid cancer, glioblastoma, astrocytoma, kolangiocarcinoma, lymphoma mariyu itarulu unnaaru.
samajam mariyu samskruti.
chattaparamaina sthithi.
idhi augustu augustu united stateslo mariyu mae mae australialo vaidya upayogam kosam aamodinchabadindi.
aardhikasaastram.
entrectinib yokka parisoedhanalu ignita pharmaceuticals dwara nirvahinchabaddaayi. 2017 december 21naa, roche $1.7 biliyanlaku ignitaanu konugolu chese pranaalikalanu prakatinchaaru.
paerlu.
entrectinib anedi antarjaateeya yajamanya namam (inn). 

